FDA Approves Cobenfy, Pioneering New Approach to Schizophrenia Treatment
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This innovative medication marks a significant …
FDA Approves Cobenfy, Pioneering New Approach to Schizophrenia Treatment Read More